Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Gains from Sales and Divestitures: 2017-2024

Historic Gains from Sales and Divestitures for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $1.5 million.

  • Aclaris Therapeutics' Gains from Sales and Divestitures rose 12.16% to $608,833 in Q3 2025 from the same period last year, while for Sep 2025 it was $608,833, marking a year-over-year increase of 12.16%. This contributed to the annual value of $1.5 million for FY2024, which is 97.69% up from last year.
  • As of FY2024, Aclaris Therapeutics' Gains from Sales and Divestitures stood at $1.5 million, which was up 97.69% from $745,279 recorded in FY2023.
  • Over the past 5 years, Aclaris Therapeutics' Gains from Sales and Divestitures peaked at $1.8 million during FY2020, and registered a low of $533,212 during FY2022.
  • Its 3-year average for Gains from Sales and Divestitures is $917,273, with a median of $745,279 in 2023.
  • In the last 5 years, Aclaris Therapeutics' Gains from Sales and Divestitures spiked by 940.35% in 2020 and then tumbled by 60.21% in 2022.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Gains from Sales and Divestitures stood at $1.8 million in 2020, then fell by 25.74% to $1.3 million in 2021, then slumped by 60.21% to $533,212 in 2022, then surged by 39.77% to $745,279 in 2023, then spiked by 97.69% to $1.5 million in 2024.